Work

B-PRISM (Precision Intervention Smoldering Myeloma): A phase II trial of combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.8040

Authors: Omar Nadeem, Robert Redd, Clifton Craig Mo, Jacob Laubach, Julia Prescott, Amada Metivier, Christine Davie, Meredith Bertoni, Elizabeth Murphy, Brian Sheehan, Kelsey Tague, Hira Shrestha, Rebekah Medina, Alexandra Distaso, Houry Leblebjian, Paul G. Richardson, Irene M. Ghobrial

Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Janssen Biotech

OpenAlex ID: W4281624315

Cites:

Cited by: 7

Related to: 10